洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR2600133347】Risk Factor Identification of Dementia and Development of Hong Kong Dementia Registry

基本信息
登记号

ChiCTR2600133347

试验状态

尚未开始

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2026-09-24

临床申请受理号

/

靶点

/

适应症

dementia

试验通俗题目

Risk Factor Identification of Dementia and Development of Hong Kong Dementia Registry

试验专业题目

Risk Factor Identification of Dementia and Development of Hong Kong Dementia Registry

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

000000

联系人通讯地址
请登录查看
临床试验信息
试验目的

1. To estimate the population attributable fractions of established modifiable risk factors for incident dementia in older adults in Hong Kong using locally derived prevalence and effect size estimates. 2. To identify additional sociodemographic, clinical, lifestyle, and psychosocial risk and protective factors for incident dementia and cognitive decline in the Hong Kong Chinese population. 3. To establish a territory-wide Hong Kong Dementia Registry capturing standardised clinical characteristics and longitudinal data on cognition, functional abilities, comorbidities, treatment, health and social service usage, and survival.

试验分类
请登录查看
试验类型

队列研究

试验分期

其它

随机化

No randomization

盲法

None

试验项目经费来源

NA

试验范围

/

目标入组人数

50000

实际入组人数

/

第一例入组时间

2026-10-01

试验终止时间

2041-05-31

是否属于一致性

/

入选标准

Participants for Risk Factor Study Inclusion criteria 1. Aged 45 years old or above 2. Hong Kong citizens 3. Able to read Chinese 4. Able to self-complete a Chinese online dementia risk factor survey 5. Consent to participate in the risk factor study People with potential or confirmed cognitive impairment for Dementia Registry Inclusion criteria 1. Aged 45 years old or above 2. Hong Kong citizens 3. Potential or confirmed cognitive impairment (dementia is defined as AD8≧2) [58] 4. Able to take part in data collection 5. Consent to register in the Dementia Registry Caregivers of people with potential or confirmed cognitive impairment for Dementia Registry Inclusion criteria 1. Aged 18 years old or above 2. Caregivers of participants #2 3. Able to take part in data collection 4. Consent to participate in the Dementia Registry Participants for Risk Factor Study Inclusion criteria1. Aged 45 years old or above2. Hong Kong citizens3. Able to read Chinese4. Able to self-complete a Chinese online dementia risk factor survey5. Consent to participate in the risk factor studyPeople with potential or confirmed cognitive impairment for Dementia Registry Inclusion criteria1. Aged 45 years old or above2. Hong Kong citizens3. Potential or confirmed cognitive impairment (dementia is defined as AD8≧2) [58]4. Able to take part in data collection5. Consent to register in the Dementia RegistryCaregivers of people with potential or confirmed cognitive impairment for Dementia Registry Inclusion criteria1. Aged 18 years old or above2. Caregivers of participants #23. Able to take part in data collection4. Consent to participate in the Dementia Registry;

排除标准

Participants for Risk Factor Study Exclusion criteria 1. Not residing in Hong Kong 2. Unable to complete a Chinese online dementia risk factor survey 3. Not giving consent to research participation People with potential or confirmed cognitive impairment for Dementia Registry Exclusion criteria 1. Not residing in Hong Kong 2. Unable to take part in data collection 3. Not giving consent to research participation Caregivers of people with potential or confirmed cognitive impairment for Dementia Registry Exclusion criteria 1. Unable to take part in data collection 2. Not giving consent to research participation;

研究者信息
研究负责人姓名
请登录查看
试验机构

Jockey Club Centre for Positive Ageing

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

000000

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

388,096个
全球在研药物数
3,065个
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,632亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看